Intra-operative cisplatin for the treatment of canine extremity soft tissue sarcomas.
Nineteen dogs with histologically confirmed soft tissue sarcomas of the extremities were treated with a combination of marginal surgery and intra-operative chemotherapy in the form of cisplatin in a biodegradable implant delivery system (Atrigel; Atrix Laboratories, Fort Collins, Co, USA). None of the dogs had evidence of metastasis at time of treatment. The median dose of cisplatin was 52.1 mg/m(2) (mean 55.4 mg/m(2), range 18.5-108.6 mg/m(2)). Wound complications were noted in 16 dogs (84.2%). Median follow-up time was 874 days (mean 777 days, range 125-1463 days). Nine dogs (47.3%) were alive at the time of analysis. Local recurrence occurred in three dogs (16.6%). The time to recurrence was 214, 264 and 874 days.
Havlicek
M
M
Veterinary Specialist Centre, North Ryde, New South Wales, Australia. mhavlicek@vetspecialist.com.au
Straw
R S
RS
Langova
V
V
Dernell
W S
WS
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001704:Biopolymers; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D004285:Dogs; D005121:Extremities; D005260:Female; D005500:Follow-Up Studies; D007430:Intraoperative Care / Q000662:veterinary*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary*; D011446:Prospective Studies; D012509:Sarcoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000662:veterinary*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001704:Biopolymers; D002945:Cisplatin